Ironwood raises 2026 guidance again as apraglutide trial recruits and debt is repaid
The company lifted full-year LINZESS, revenue, and EBITDA guidance for a second straight quarter while its confirmatory apraglutide trial begins enrolling patients and it retires $200 million in convertible notes.
SEC filing